1Department of Radiation Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea
2Department of Radiation Oncology, St. Vincent’s Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea
3Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea
Copyright © 2015 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable |
No. of patients (%) |
p-value | |
---|---|---|---|
Non-responder (n=20) | Responder (n=75) | ||
Age (yr) | 0.51 | ||
< 70 (n=49) | 9 (18.4) | 40 (81.6) | |
≥ 70 (n=46) | 11 (23.9) | 35 (76.1) | |
Gender | 0.20 | ||
Male (n=68) | 12 (17.6) | 56 (82.4) | |
Female (n=27) | 8 (29.6) | 19 (70.4) | |
Smoking history | 0.32 | ||
Nonsmoker (n=25) | 7 (28.0) | 18 (72.0) | |
Smoker (n=70) | 13 (18.6) | 57 (81.4) | |
Clinical tumor stage | 0.67 | ||
cT0-3 (n=42) | 8 (19.0) | 34 (81.0) | |
cT4 (n=53) | 12 (22.6) | 41 (77.4) | |
Clinical nodal stage | 1.00 | ||
cN0-2 (n=38) | 8 (21.1) | 30 (78.9) | |
cN3 (n=57) | 12 (21.1) | 45 (78.9) | |
Clinical metastatic stage | 0.41 | ||
cM0 (n=31) | 5 (16.1) | 26 (83.9) | |
cM1 (n=64) | 15 (23.4) | 49 (76.6) | |
Histology | 0.76 | ||
Small cell lung cancer (n=36) | 7 (19.4) | 29 (80.6) | |
Non-small cell lung cancer (n=59) | 13 (22.0) | 46 (78.0) | |
Tumor side | 0.10 | ||
Right (n=58) | 9 (15.5) | 49 (84.5) | |
Left (n=37) | 11 (29.7) | 26 (70.3) | |
Tumor location | 0.58 | ||
Upper (n=48) | 9 (18.8) | 39 (81.3) | |
Middle and lower (n=47) | 11 (23.4) | 36 (76.6) | |
Maximal tumor size | 0.04 | ||
< 6 cm (n=48) | 6 (12.5) | 42 (87.5) | |
≥ 6 cm (n=47) | 14 (29.8) | 33 (70.2) | |
ECOG performance status | 0.21 | ||
0-1 (n=45) | 7 (15.6) | 38 (84.4) | |
2 (n=50) | 13 (26.0) | 37 (74.0) | |
BED | |||
< 39 Gya) (n=16) | 11 (68.8) | 5 (31.3) | < 0.01 |
≥ 39 Gy (n=79) | 9 (11.4) | 70 (88.6) | |
Interval between obstruction and radiotherapy | 0.32 | ||
< 8 days (n=43) | 11 (25.6) | 32 (74.4) | |
≥ 8 days (n=52) | 9 (17.3) | 43 (82.7) | |
Recurrent tumor | 0.33 | ||
No (n=74) | 14 (18.9) | 60 (81.1) | |
Yes (n=21) | 6 (28.6) | 15 (71.4) |
Complication |
Grade |
||
---|---|---|---|
2 | 3 | 4 | |
Hematologic | |||
Leucopenia | 0 | 0 | 0 |
Anemia | 0 | 0 | 0 |
Thrombocytopenia | 0 | 0 | 0 |
Non-hematologic | |||
Radiation pneumonitis | 2 (2.1) | 0 | 0 |
Pericarditis | 0 | 0 | 0 |
Esophagitis | 6 (6.3) | 0 | 0 |
Hemoptysis | 0 | 0 | 0 |
Characteristic | No. of patients (%) |
---|---|
Age (yr) | |
Median | 69 (36-85) |
< 70 | 49 (51.6) |
≥ 70 | 46 (48.4) |
Gender | |
Male | 68 (71.6) |
Female | 27 (28.4) |
Smoking history | |
Non-smoker | 25 (26.3) |
Smoker | 70 (73.7) |
Clinical tumor stage | |
cT1 | 6 (6.3) |
cT2 | 15 (15.8) |
cT3 | 21 (22.1) |
cT4 | 53 (55.8) |
Clinical nodal stage | |
cN0 | 6 (6.3) |
cN1 | 2 (2.1) |
cN2 | 30 (31.6) |
cN3 | 57 (60.0) |
Clinical metastatic stage | |
cM0 | 31 (32.6) |
cM1 | 64 (67.4) |
Histology | |
Small cell lung cancer | 36 (37.9) |
Non-small cell lung cancer | 59 (62.1) |
Tumor side | |
Right | 58 (61.1) |
Left | 37 (38.9) |
Tumor location | |
Upper lobe | 48 (50.5) |
Middle lobe | 33 (34.7) |
Lower lobe | 14 (14.7) |
ECOG performance status | |
0 | 5 (5.3) |
1 | 40 (42.1) |
2 | 50 (52.6) |
Previous treatment | |
None | 49 (51.6) |
Chemotherapy | 45 (47.4) |
Surgery | 1 (1.0) |
Variable | No. of patients (%) |
p-value | |
---|---|---|---|
Non-responder (n=20) | Responder (n=75) | ||
Age (yr) | 0.51 | ||
< 70 (n=49) | 9 (18.4) | 40 (81.6) | |
≥ 70 (n=46) | 11 (23.9) | 35 (76.1) | |
Gender | 0.20 | ||
Male (n=68) | 12 (17.6) | 56 (82.4) | |
Female (n=27) | 8 (29.6) | 19 (70.4) | |
Smoking history | 0.32 | ||
Nonsmoker (n=25) | 7 (28.0) | 18 (72.0) | |
Smoker (n=70) | 13 (18.6) | 57 (81.4) | |
Clinical tumor stage | 0.67 | ||
cT0-3 (n=42) | 8 (19.0) | 34 (81.0) | |
cT4 (n=53) | 12 (22.6) | 41 (77.4) | |
Clinical nodal stage | 1.00 | ||
cN0-2 (n=38) | 8 (21.1) | 30 (78.9) | |
cN3 (n=57) | 12 (21.1) | 45 (78.9) | |
Clinical metastatic stage | 0.41 | ||
cM0 (n=31) | 5 (16.1) | 26 (83.9) | |
cM1 (n=64) | 15 (23.4) | 49 (76.6) | |
Histology | 0.76 | ||
Small cell lung cancer (n=36) | 7 (19.4) | 29 (80.6) | |
Non-small cell lung cancer (n=59) | 13 (22.0) | 46 (78.0) | |
Tumor side | 0.10 | ||
Right (n=58) | 9 (15.5) | 49 (84.5) | |
Left (n=37) | 11 (29.7) | 26 (70.3) | |
Tumor location | 0.58 | ||
Upper (n=48) | 9 (18.8) | 39 (81.3) | |
Middle and lower (n=47) | 11 (23.4) | 36 (76.6) | |
Maximal tumor size | 0.04 | ||
< 6 cm (n=48) | 6 (12.5) | 42 (87.5) | |
≥ 6 cm (n=47) | 14 (29.8) | 33 (70.2) | |
ECOG performance status | 0.21 | ||
0-1 (n=45) | 7 (15.6) | 38 (84.4) | |
2 (n=50) | 13 (26.0) | 37 (74.0) | |
BED | |||
< 39 Gy |
11 (68.8) | 5 (31.3) | < 0.01 |
≥ 39 Gy (n=79) | 9 (11.4) | 70 (88.6) | |
Interval between obstruction and radiotherapy | 0.32 | ||
< 8 days (n=43) | 11 (25.6) | 32 (74.4) | |
≥ 8 days (n=52) | 9 (17.3) | 43 (82.7) | |
Recurrent tumor | 0.33 | ||
No (n=74) | 14 (18.9) | 60 (81.1) | |
Yes (n=21) | 6 (28.6) | 15 (71.4) |
Complication | Grade |
||
---|---|---|---|
2 | 3 | 4 | |
Hematologic | |||
Leucopenia | 0 | 0 | 0 |
Anemia | 0 | 0 | 0 |
Thrombocytopenia | 0 | 0 | 0 |
Non-hematologic | |||
Radiation pneumonitis | 2 (2.1) | 0 | 0 |
Pericarditis | 0 | 0 | 0 |
Esophagitis | 6 (6.3) | 0 | 0 |
Hemoptysis | 0 | 0 | 0 |
ECOG, Eastern Cooperative Oncology Group.
ECOG, eastern cooperative oncology group; BED, biologically effective dose. Biologically effective dose for the radiation schedule of 30 Gy in 10 fractions for two weeks is 39 Gy when α / β ratio is assumed to be 10 for early responding tissues.
Values are presented as number of patients (%).